Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease

Exclusion Criteria

• •1. Supplement with probiotic/prebiotic within 2 weeks
• •2. Previous antibiotic/antifungus within 1 month
• •3. History of significant alcohol consumption for a period of more than three consecutive months within 1 year before screening. Significant alcohol consumption is defined as equal to or greater than approximately two alcoholic drinks per day for males and approximately 1.5 alcoholic drinks per day for females
• •4. Regular use of drugs historically associated with NAFLD, which include, but are not limited, to the following: amiodarone, methotrexate, systemic glucocorticoids at greater than 5 mg/d
• •5. Chronic liver diseases from other cause such as viral hepatitis, autoimmune hepatitis
• •6. Hepatic decompensation or impairment defined as presence of any of the following:
• •* History of esophageal varices, ascites or hepatic encephalopathy.
• •* Serum albumin \<3.5 g dl-1, except as explained by nonhepatic causes.
• •* INR \> 1.4
• •7. Use of GLP-1 agonist therapy (for example, exenatide, liraglutide, lixisenatide, albiglutide, dulaglutide, semaglutide and albiglutide), vitamin E and pioglitazone
• •8. Active autoimmune disease, including actively treated lupus, rheumatoid arthritis, inflammatory bowel disease
• •9. Active malignancy on treatment
• •10. New York Heart Association Class III or IV heart failure or known left ventricular ejection fraction \<30%
• •11. Known immunocompromised status, HIV or who have recurrent or chronic systemic bacterial, fungal, viral or protozoal infections
• •12. Respiratory compromised
• •13. Severe renal impairment (eGFR \<30 ml/min/1.73 m2)
• •14. Pregnancy